Noopept vs P21
A side-by-side research comparison of Noopept and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Noopept | P21 |
|---|---|---|
| Full name | Noopept (GVS-111) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 318.4 Da | ~450 Da |
| Half-life | 30-60 minutes (active metabolite longer) | 4-6 hours |
| Bioavailability | High (oral/sublingual) | Moderate (crosses BBB) |
| Typical dose | 10-30 mg | 50-100 mcg/kg |
| Frequency | 2-3x daily | Daily |
| Route | Oral or Sublingual | Intranasal or Subcutaneous |
Noopept reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.